| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Carmen Peña-Bautista, Lidia Flor, Marina López-Nogueroles, Lorena García, Inés Ferrer, Miguel Baquero, Máximo Vento, Consuelo Cháfer-Pericá. Plasma alterations in cholinergic and serotonergic systems in early Alzheimer Disease: Diagnosis utility. Clinica chimica acta; international journal of clinical chemistry. vol 500. 2020-06-02. PMID:31678274. |
plasma alterations in cholinergic and serotonergic systems in early alzheimer disease: diagnosis utility. |
2020-06-02 |
2023-08-13 |
Not clear |
| Bernadet L Klaassens, Joop M A van Gerven, Erica S Klaassen, Jeroen van der Grond, Serge A R B Rombout. Cholinergic and serotonergic modulation of resting state functional brain connectivity in Alzheimer's disease. NeuroImage. vol 199. 2020-02-26. PMID:31112788. |
cholinergic and serotonergic modulation of resting state functional brain connectivity in alzheimer's disease. |
2020-02-26 |
2023-08-13 |
human |
| Bernadet L Klaassens, Joop M A van Gerven, Erica S Klaassen, Jeroen van der Grond, Serge A R B Rombout. Cholinergic and serotonergic modulation of resting state functional brain connectivity in Alzheimer's disease. NeuroImage. vol 199. 2020-02-26. PMID:31112788. |
disruption of cholinergic and serotonergic neurotransmitter systems is associated with cognitive, emotional and behavioural symptoms of alzheimer's disease (ad). |
2020-02-26 |
2023-08-13 |
human |
| Saikat Chakraborty, Jack C Lennon, Sridhar A Malkaram, Yan Zeng, Daniel W Fisher, Hongxin Don. Serotonergic system, cognition, and BPSD in Alzheimer's disease. Neuroscience letters. vol 704. 2020-02-05. PMID:30946928. |
serotonergic system, cognition, and bpsd in alzheimer's disease. |
2020-02-05 |
2023-08-13 |
Not clear |
| Agnieszka Jankowska, Anna Wesolowska, Maciej Pawlowski, Grazyna Chlon-Rzep. Multi-Target-Directed Ligands Affecting Serotonergic Neurotransmission for Alzheimer's Disease Therapy: Advances in Chemical and Biological Research. Current medicinal chemistry. vol 25. issue 17. 2018-11-20. PMID:28554324. |
multi-target-directed ligands affecting serotonergic neurotransmission for alzheimer's disease therapy: advances in chemical and biological research. |
2018-11-20 |
2023-08-13 |
Not clear |
| Costa Vakalopoulo. Alzheimer's Disease: The Alternative Serotonergic Hypothesis of Cognitive Decline. Journal of Alzheimer's disease : JAD. vol 60. issue 3. 2018-05-30. PMID:28984594. |
alzheimer's disease: the alternative serotonergic hypothesis of cognitive decline. |
2018-05-30 |
2023-08-13 |
mouse |
| Costa Vakalopoulo. Alzheimer's Disease: The Alternative Serotonergic Hypothesis of Cognitive Decline. Journal of Alzheimer's disease : JAD. vol 60. issue 3. 2018-05-30. PMID:28984594. |
recent pre-clinical studies on app/ps1 (familial alzheimer's disease) transgenic mouse models using serotonergic receptor modulating agents, demonstrate clear neuroprotective effects. |
2018-05-30 |
2023-08-13 |
mouse |
| Christian Ulrich von Linstow, Jonas Waider, Manuela Grebing, Athanasios Metaxas, Klaus Peter Lesch, Bente Finse. Serotonin augmentation therapy by escitalopram has minimal effects on amyloid-β levels in early-stage Alzheimer's-like disease in mice. Alzheimer's research & therapy. vol 9. issue 1. 2018-05-17. PMID:28899417. |
dysfunction of the serotonergic (5-htergic) system has been implicated in the cognitive and behavioural symptoms of alzheimer's disease (ad). |
2018-05-17 |
2023-08-13 |
mouse |
| Mathieu Verdurand, Luc Zimme. Hippocampal 5-HT Neuropharmacology. vol 123. 2018-04-17. PMID:28647411. |
hippocampal 5-ht there is increasing evidence that the serotonergic system is highly dysfunctional in alzheimer's disease (ad), and this could be related to cognitive impairments associated with dementia. |
2018-04-17 |
2023-08-13 |
Not clear |
| Christine M Dengler-Crish, Matthew A Smith, Gina N Wilso. Early Evidence of Low Bone Density and Decreased Serotonergic Synthesis in the Dorsal Raphe of a Tauopathy Model of Alzheimer's Disease. Journal of Alzheimer's disease : JAD. vol 55. issue 4. 2018-02-20. PMID:27814296. |
early evidence of low bone density and decreased serotonergic synthesis in the dorsal raphe of a tauopathy model of alzheimer's disease. |
2018-02-20 |
2023-08-13 |
mouse |
| Walid Tajeddinn, Torbjörn Persson, Javier Calvo-Garrido, Mohammed Seed Ahmed, Silvia Maioli, Swetha Vijayaraghavan, Mehmet Selim Kazokoglu, Cristina Parrado-Fernández, Takashi Yoshitake, Jan Kehr, Paul Francis, Bengt Winblad, Kina Höglund, Angel Cedazo-Minguez, Dag Aarslan. Pharmacological Modulations of the Serotonergic System in a Cell-Model of Familial Alzheimer's Disease. Journal of Alzheimer's disease : JAD. vol 53. issue 1. 2018-01-29. PMID:27163814. |
pharmacological modulations of the serotonergic system in a cell-model of familial alzheimer's disease. |
2018-01-29 |
2023-08-13 |
Not clear |
| Yannick Vermeiren, Jana Janssens, Tony Aerts, Jean-Jacques Martin, Anne Sieben, Debby Van Dam, Peter P De Dey. Brain Serotonergic and Noradrenergic Deficiencies in Behavioral Variant Frontotemporal Dementia Compared to Early-Onset Alzheimer's Disease. Journal of Alzheimer's disease : JAD. vol 53. issue 3. 2018-01-29. PMID:27314528. |
brain serotonergic and noradrenergic deficiencies in behavioral variant frontotemporal dementia compared to early-onset alzheimer's disease. |
2018-01-29 |
2023-08-13 |
human |
| Felix-Martin Werner, Rafael Covena. Serotonergic Drugs: Agonists/Antagonists at Specific Serotonergic Subreceptors for the Treatment of Cognitive, Depressant and Psychotic Symptoms in Alzheimer's Disease. Current pharmaceutical design. vol 22. issue 14. 2017-11-16. PMID:26818863. |
serotonergic drugs: agonists/antagonists at specific serotonergic subreceptors for the treatment of cognitive, depressant and psychotic symptoms in alzheimer's disease. |
2017-11-16 |
2023-08-13 |
Not clear |
| Disha Shah, Ines Blockx, Georgios A Keliris, Firat Kara, Elisabeth Jonckers, Marleen Verhoye, Annemie Van der Linde. Cholinergic and serotonergic modulations differentially affect large-scale functional networks in the mouse brain. Brain structure & function. vol 221. issue 6. 2017-09-28. PMID:26195064. |
the cholinergic system is involved in cognitive functions and is impaired in, e.g., alzheimer's disease, while the serotonergic system is involved in emotional and introspective functions and is impaired in, e.g., alzheimer's disease, depression and autism. |
2017-09-28 |
2023-08-13 |
mouse |
| Alexander Wirth, Katrin Holst, Evgeni Ponimaski. How serotonin receptors regulate morphogenic signalling in neurons. Progress in neurobiology. vol 151. 2017-07-11. PMID:27013076. |
imbalance in serotonergic signalling is implicated in many pathophysiological conditions, including schizophrenia, alzheimer's disease, depression, and anxiety. |
2017-07-11 |
2023-08-13 |
Not clear |
| Massimiliano Buoli, Marta Serati, Alice Caldiroli, Daniela Galimberti, Elio Scarpini, Alfredo Carlo Altamur. Pharmacological Management of Psychiatric Symptoms in Frontotemporal Dementia: A Systematic Review. Journal of geriatric psychiatry and neurology. vol 30. issue 3. 2017-04-27. PMID:28351199. |
although drugs for alzheimer disease appear to be ineffective for the treatment of psychiatric symptoms of ftd, preliminary evidence supports a possible usefulness of serotonergic antidepressants for these patients. |
2017-04-27 |
2023-08-13 |
Not clear |
| Samir Yahiaoui, Katia Hamidouche, Céline Ballandonne, Audrey Davis, Jana Sopkova de Oliveira Santos, Thomas Freret, Michel Boulouard, Christophe Rochais, Patrick Dallemagn. Design, synthesis, and pharmacological evaluation of multitarget-directed ligands with both serotonergic subtype 4 receptor (5-HT4R) partial agonist and 5-HT6R antagonist activities, as potential treatment of Alzheimer's disease. European journal of medicinal chemistry. vol 121. 2017-02-13. PMID:27266998. |
design, synthesis, and pharmacological evaluation of multitarget-directed ligands with both serotonergic subtype 4 receptor (5-ht4r) partial agonist and 5-ht6r antagonist activities, as potential treatment of alzheimer's disease. |
2017-02-13 |
2023-08-13 |
mouse |
| Anand Kant Das, Rucha Pandit, Sudipta Mait. Effect of amyloids on the vesicular machinery: implications for somatic neurotransmission. Philosophical transactions of the Royal Society of London. Series B, Biological sciences. vol 370. issue 1672. 2016-02-16. PMID:26009766. |
a disruption of the vesicular machinery can also be deleterious for extra-synaptic, especially somatic, neurotransmission (common in serotonergic and dopaminergic systems which are specifically affected in alzheimer's disease (ad) and parkinson's disease (pd), respectively), though this relationship has remained unexplored. |
2016-02-16 |
2023-08-13 |
Not clear |
| Rodrigo Arreola, Enrique Becerril-Villanueva, Carlos Cruz-Fuentes, Marco Antonio Velasco-Velázquez, María Eugenia Garcés-Alvarez, Gabriela Hurtado-Alvarado, Saray Quintero-Fabian, Lenin Pavó. Immunomodulatory effects mediated by serotonin. Journal of immunology research. vol 2015. 2016-02-01. PMID:25961058. |
major depression, fibromyalgia, alzheimer disease, psoriasis, arthritis, allergies, and asthma are all associated with changes in the serotonergic system associated with leukocytes. |
2016-02-01 |
2023-08-13 |
Not clear |
| Walid Tajeddinn, Torbjörn Persson, Silvia Maioli, Javier Calvo-Garrido, Cristina Parrado-Fernandez, Takashi Yoshitake, Jan Kehr, Paul Francis, Bengt Winblad, Kina Höglund, Angel Cedazo-Minguez, Dag Aarslan. 5-HT1B and other related serotonergic proteins are altered in APPswe mutation. Neuroscience letters. vol 594. 2015-09-14. PMID:25841787. |
serotonergic dysfunction is implicated in alzheimer's disease (ad). |
2015-09-14 |
2023-08-13 |
mouse |